CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
进展中的肿瘤免疫治疗——过去 130 年概述
英文原题：Cancer immunotherapy in progress-an overview of the past 130 years.
查看英文原题
Cancer immunotherapy in progress-an overview of the past 130 years.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
自免疫检查点抑制剂首次获批以来，我们见证了癌症免疫治疗的临床成功。使用CAR-T（CAR-T）细胞的过继性T细胞疗法在血液系统恶性肿瘤中显示出显著疗效。与这些成功同时，完善了癌症免疫监视概念的癌症免疫编辑概念，为过去的失败以及近期癌症免疫治疗的突破提供了科学机制和原因。现在，我们面临该领域下一步需要解决的问题，例如肿瘤异质性、肿瘤微环境、肿瘤与免疫系统的代谢，以及针对患者的个性化方法，旨在扩大受益于这些疗法的群体。
展开英文摘要原文
Since the first approval of an immune checkpoint inhibitor, we have witnessed the clinical success of cancer immunotherapy. Adoptive T-cell therapy with chimeric antigen receptor T (CAR-T) cells has shown remarkable efficacy in hematological malignancies. Concurrently with these successes, the cancer immunoediting concept that refined the cancer immunosurveillance concept underpinned the scientific mechanism and reason for past failures, as well as recent breakthroughs in cancer immunotherapy.
Now, we face the next step of issues to be solved in this field, such as tumor heterogeneity, the tumor microenvironment, the metabolism of tumors and the immune system, and personalized approaches for patients, aiming to expand the population benefitted by the therapies.
论文信息
- 作者
- Ikeda H
- 单位
- Department of Oncology, Nagasaki University Graduate School of Biomedical Sciences, 1-12-4, Sakamoto, Nagasaki 852-8523, Japan.Japan
- 文献类型
- 综述 · 历史回顾 · 非美国政府资助研究
- 期刊
- International immunology2025 Apr 7
- 原文标识
- PubMed 39792088 · DOI 10.1093/intimm/dxaf002
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →